Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company specializing in allergic and immunological diseases, has announced its participation in the 2024 Wedbush PacGrow Healthcare Conference in New York, NY. The company's CEO, Jill C. Milne, Ph.D., will be part of a panel discussion titled 'HAE Ya! The Changing Face of the HAE Therapeutic Landscape' on Wednesday, August 14 at 2:30pm ET.
This panel will focus on hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling in various parts of the body. Astria's participation in this conference highlights its commitment to advancing therapies for HAE and other immunological conditions, potentially impacting its stock performance and investor interest in the biopharmaceutical sector.
Astria Therapeutics, Inc. (Nasdaq: ATXS), un'azienda biofarmaceutica specializzata in malattie allergiche e immunologiche, ha annunciato la sua partecipazione alla 2024 Wedbush PacGrow Healthcare Conference a New York, NY. L'amministratore delegato dell'azienda, Jill C. Milne, Ph.D., prenderà parte a una tavola rotonda intitolata 'HAE Ya! Il cambiamento nel panorama terapeutico dell'HAE' mercoledì 14 agosto alle 14:30 ET.
Questa discussione si concentrerà sull'angioedema ereditario (HAE), un raro disturbo genetico che causa grave gonfiore in diverse parti del corpo. La partecipazione di Astria a questa conferenza evidenzia il suo impegno ad avanzare le terapie per l'HAE e altre condizioni immunologiche, potenzialmente influenzando le performance azionarie e l'interesse degli investitori nel settore biofarmaceutico.
Astria Therapeutics, Inc. (Nasdaq: ATXS), una compañía biofarmacéutica especializada en enfermedades alérgicas e inmunológicas, ha anunciado su participación en la 2024 Wedbush PacGrow Healthcare Conference en Nueva York, NY. La CEO de la compañía, Jill C. Milne, Ph.D., será parte de una discusión en panel titulada 'HAE Ya! El rostro cambiante del panorama terapéutico del HAE' el miércoles 14 de agosto a las 2:30 p.m. ET.
Este panel se centrará en el angioedema hereditario (HAE), un raro trastorno genético que causa una inflamación severa en varias partes del cuerpo. La participación de Astria en esta conferencia destaca su compromiso de avanzar en las terapias para el HAE y otras condiciones inmunológicas, lo que podría impactar su rendimiento accionario y el interés de los inversores en el sector biofarmacéutico.
Astria Therapeutics, Inc. (Nasdaq: ATXS)는 알레르기 및 면역 질환을 전문으로 하는 생물 제약 회사로, 뉴욕 NY에서 개최되는 2024 Wedbush PacGrow Healthcare Conference에 참여한다고 발표했습니다. 회사의 CEO인 Jill C. Milne, Ph.D.는 'HAE Ya! HAE 치료 환경의 변화'라는 제목의 패널 토론에 참여할 예정입니다. 이 토론은 유전성 혈관 부종(HAE), 신체 여러 부위에서 심한 부종을 유발하는 희귀 유전 질환에 초점을 맞출 것입니다. Astria의 이번 회의 참여는 HAE 및 기타 면역 관련 질환에 대한 치료법을 발전시키려는 의지를 강조하며, 이는 주식 성과와 생물 제약 분야 투자자들의 관심에 잠재적인 영향을 미칠 수 있습니다.
Astria Therapeutics, Inc. (Nasdaq: ATXS), une société biopharmaceutique spécialisée dans les maladies allergiques et immunologiques, a annoncé sa participation à la 2024 Wedbush PacGrow Healthcare Conference à New York, NY. La PDG de l'entreprise, Jill C. Milne, Ph.D., participera à une table ronde intitulée 'HAE Ya! Le visage changeant du paysage thérapeutique de l'HAE' le mercredi 14 août à 14h30 ET.
Ce panel se concentrera sur l'angioœdème héréditaire (HAE), un trouble génétique rare qui provoque un gonflement sévère dans différentes parties du corps. La participation d'Astria à cette conférence souligne son engagement à faire progresser les thérapies pour l'HAE et d'autres conditions immunologiques, ce qui pourrait potentiellement avoir un impact sur la performance de ses actions et l'intérêt des investisseurs dans le secteur biopharmaceutique.
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das sich auf allergische und immunologische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 2024 Wedbush PacGrow Healthcare Conference in New York, NY, angekündigt. Die Geschäftsführerin des Unternehmens, Jill C. Milne, Ph.D., wird an einer Podiumsdiskussion mit dem Titel 'HAE Ya! Das sich verändernde Gesicht der therapeutischen Landschaft des HAE' am Mittwoch, den 14. August um 14:30 Uhr ET, teilnehmen.
Diese Diskussion wird sich auf hereditäres Angioödem (HAE), eine seltene genetische Erkrankung, die schwere Schwellungen in verschiedenen Körperregionen verursacht, konzentrieren. Die Teilnahme von Astria an dieser Konferenz unterstreicht ihr Engagement, Therapien für HAE und andere immunologische Zustände voranzutreiben, was potenziell die Aktienentwicklung und das Investoreninteresse im biopharmazeutischen Sektor beeinflussen könnte.
- None.
- None.
Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “HAE Ya! The Changing Face of the HAE Therapeutic Landscape” on Wednesday, August 14 at 2:30pm ET.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807566138/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When is Astria Therapeutics (ATXS) participating in the 2024 Wedbush PacGrow Healthcare Conference?
What panel is Astria Therapeutics' CEO participating in at the Wedbush conference?
What is the focus of Astria Therapeutics' (ATXS) research and development?
How might Astria Therapeutics' (ATXS) participation in the Wedbush conference affect its stock?
